Piperacillin-Tazobactam
- Generic Name
- Piperacillin-Tazobactam
- Indication
适用于产β内酰胺酶而对哌拉西林耐药、但对本品敏感的细菌（如大肠埃希菌、克雷伯菌属、柠檬酸杆菌属、肠杆菌属、沙雷菌属、变形杆菌属、摩根菌属、雷极普罗维登菌、铜绿假单胞菌、流感嗜血杆菌、不动杆菌属、葡萄球菌属和拟杆菌属等）所致的下列中、重度感染：
1.肺炎、肺脓肿、脓胸、支气管扩张合并感染和慢性阻塞性肺病继发性感染等下呼吸道感染；
2.创伤或外科伤口继发皮肤软组织感染、蜂窝织炎、皮肤脓肿、糖尿病足感染；
3.胆囊炎、胆管炎、肝脓肿和腹膜炎等腹腔感染；
4.盆腔炎、子宫内膜炎、子宫周围炎、附件炎、盆腔脓肿等生殖系统感染；
5.单纯或复杂性尿路感染。本品用于铜绿假单胞菌严重感染时，应联合氨基糖苷类等其他抗铜绿假单胞菌的药物。
A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients
- Conditions
- Acute Kidney Injury
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 750
- Registration Number
- NCT06954129
Aminoglycosides in Early Sepsis
- Conditions
- Sepsis
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 1940
- Registration Number
- NCT06712641
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Norway
🇳🇴Oslo University Hospital Ullevål, Oslo, Norway
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity
- Conditions
- InfectionsObesity and Obesity-related Medical Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
- Target Recruit Count
- 60
- Registration Number
- NCT06690905
- Locations
- 🇨🇦
Hôpital Charles- Le Moyne, Greenfield Park, Quebec, Canada
Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
- Conditions
- Febrile Neutropenia
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 30
- Registration Number
- NCT06293677
- Locations
- 🇨🇭
Centre Hospitelier Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- Drug: Imipenem/Cilastatin/Relebactam
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04983901
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
- Conditions
- Enterobacteriaceae Infections
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 9
- Registration Number
- NCT04276480
- Locations
- 🇫🇷
Centre hospitalier de la Côte Basque, Bayonne, France
🇫🇷Hopital Pellegrin, Bordeaux, France
Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients
- Conditions
- Febrile Neutropenia
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Hospital Universitari de Bellvitge
- Target Recruit Count
- 150
- Registration Number
- NCT04233996
- Locations
- 🇪🇸
Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT03922451
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
- Conditions
- Graft-versus-host Disease Prevention
- Interventions
- Procedure: Fecal Microbiota TransplantationOther: Best Practice
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03862079
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Conditions
- Other Infectious Diseases
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03485950
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.